Geron Announces Conference Call on September 12 at 8:00 A.M. Eastern Time
September 11 2016 - 7:30AM
Geron Corporation (Nasdaq:GERN) will host a conference call on
September 12, 2016, at 8:00 a.m. Eastern Time to provide an update
on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3
trial in myelodysplastic syndromes.
Participants can access the conference call live via telephone
by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The
conference ID is 80522983. If accessing the conference call by
telephone, please dial in at least 10 minutes early to minimize any
delay in joining the call. A live audio-only webcast will also be
available through the company’s website at www.geron.com under
Events. The audio webcast of the conference call will be available
for replay approximately one hour following the live broadcast
through October 13, 2016.
About Geron
Geron is a clinical stage biopharmaceutical company focused on
the collaborative development of a first-in-class telomerase
inhibitor, imetelstat, in hematologic myeloid malignancies. For
more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2023 to Apr 2024